• linkedin
  • Increase Font
  • Sharebar

    Alpha-blockers top choice for first-line LUTS treatment

    TURP remains most common surgical modality, survey findings indicate

    Stockholm, SwedenMost urologists turn to alpha-blockers as first-line treatment for BPH-related lower urinary tract symptoms, while transurethral resection of the prostate remains the most commonly used surgical modality, according to a recent survey.

    Roman Sosnowski, MD, PhD, of the uro-oncology department at Cancer Memorial Hospital in Warsaw, Poland, reported on the results of the survey developed by the Young Academic Urologist BPH Group, at the European Association of Urology annual congress in Stockholm, Sweden.

    The comprehensive survey was carried out via a free online tool using the EAU Newsletter, which is released once per month and distributed via email to about 2,000 members of the European Association of Urology.

    The purpose-built questionnaire was comprised of 28 questions that focused on general urologic practice, diagnosis, and medical and surgical management of patients with LUTS due to benign prostatic obstruction (BPO).

    Of the EAU members who received the questionnaire, 637 urologists replied. The majority of the respondents were younger than 50 years of age (489/637, 77%); 279 (44%) worked in an academic hospital; and 109 (17%) practiced in private clinics.

    Roughly half of the urologists (55%) reported that treating LUTS patients comprised between 20% and 50% of their activities. The survey showed that 29% of patients with BPH/LUTS are treatment naïve upon first presentation.

    Three-quarters of all respondents (74%) considered history taking, International Prostate Symptom Score (IPSS), uroflowmetry, post-void residual measurement, and PSA testing to be mandatory diagnostics prior to any surgical intervention.

    Alpha-blockers were the first line of treatment for LUTS for 79% of urologists. The second line of treatment was the addition of a 5-alpha-reductase inhibitor (49%).

    Continue to next page for more.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available